Why is Covaxin not in the FDA’s toolbox?
“As a clinician who has received two Pfizer doses and a booster without any side effects, I wholeheartedly embrace vaccination to solve this pressing public health crisis. The key is for policymakers to identify the best tool for the job (i.e., Covaxin) and utilize it effectively to solve the widest-ranging public health crisis of the past century.”
Tayson DeLengocky is an ophthalmologist.
He shares his story and discusses his KevinMD article, “Why is the world’s first universal coronavirus vaccine not in the FDA’s toolbox?“
Reflect and earn 1.0 AMA PRA Category 1 CME for this episode.
This episode is sponsored by Athelas, the number one provider of remote patient monitoring.
Did you know more than 65 percent of doctors are actively investing in remote patient monitoring?
That’s because RPM is the fastest-growing segment in health care today. And for good reason:
RPM boosts patient outcomes through preventative care. In fact, a recent study by the VA showed that implementing RPM at a practice can reduce hospital readmission rates by as much as 25 percent, saving more than $20,000 per patient in medical costs.
If you’re not investing in RPM, you’re missing out. Luckily, Athelas can help you roll out RPM end-to-end. They provide devices to your patients, handle 100 percent of billing, and even provide a team of nurses to monitor patient vitals for you. All at zero net cost to your practice.
Try out RPM for your practice by going to KevinMD.com/tryrpm.
Did you enjoy today’s episode?
Rate and review the show so more audiences can find The Podcast by KevinMD.
Subscribe on your favorite podcast app to get notified when a new episode comes out.
